Pfizer appoints DLA litigation chief as new GC

Pfizer has snared DLA Piper’s co-head of its class action practice group to be its vice president and global general counsel.

Amy Schulman will join the pharmaceutical group next month to lead the group’s executive leadership team replacing former general counsel Allen Waxman who left the company in March this year for personal reasons.

At DLA Piper Schulman advised on a number of Pfizer class actions. Last year she was lead counsel in the multi-district litigation involving Bextra and Celebrax.

Pfizer chairman and chief executive officer, Jeffrey Kindler, said: “We are fortunate to have someone of her calibre join Pfizer. We know first hand the outstanding qualities that Amy brings to us. Her knowledge of the legal, business and regulatory challenges facing the pharmaceutical industry and her experience tackling large cases makes her qualified to lead the legal team.”

Schulman joined DLA Piper in 1997 and has been a part of the firm’s global board and US executive committee. She has also been instrumental in developing a number of firmwide strategies in client services, diversity and mentoring.